

Józef Opara¹, Jarosław Szczygieł¹, Anna Tomasova², Dagmar Ballayova², Slavomir Guťan², Barbora Garajová², Tatiana Holovičvá², Patricia Tršková²

¹ Poland, ² Slovakia

NurAiD II (MLC901) IN POST STROKE RECOVERY AT CHRONIC STAGE: PRELIMINARY RESULTS OF POLISH-SLOVAC STUDY

INTRODUCTION. Treatments for stroke and other brain injuries are limited. NurAiD II (MLC 901) is a combination of 9 herbal components and has been used to improve recovery after ischemic stroke.

Aim. The aim of this study was to assess the safety and potential efficacy of NurAiD II after stroke, no later than six months from index stroke. Two Polish and six Slovak investigators has been involved in this study.

MATERIAL AND METHODS: The NeuroAiD Safe Treatment (NeST) Registry ([clinicaltrials.gov NCT02536079](https://clinicaltrials.gov/NCT02536079)) is a product registry -used to collect information on the use and safety of NeuroAiD in clinical practice. We analysed anonymised information of ischemic injury from Poland and Slovakia that was included in the NeST Registry (www.neuroaid.com/en/nest/main/index).

Data from patients consented are prospectively entered using online forms for baseline and subsequent visits at M(month)1, M2 and M3. Data collected include demographics, diagnosis, medical history, modified Rankin Score (mRS), Glasgow Coma Scale (GCS) , National Institutes of Health Stroke Scale (NIHSS), compliance and side effects.

RESULTS: Forty-two patients from Slovakia and Poland were included with mean age of 62.54 ± 11.22 years, and 21 (50.00%) women. The mean time between stroke onset and NurAiD II start was 97.98 ± 159.25 days. Median NIHSS score for the patients was 7.5 (1-26) at baseline (B), 6.0 (0-19) at M 1, 4.5 (0-16) at M2 and 3 (0-15) at M3 (Figure 1). After three months, the mRS score was improving over time (Figure 2). There were no side effects reported. Two patients were lost of follow-up.

CONCLUSIONS: NurAiD II was safe in ischemic stroke. The improvement of neurological and functional measures has been observed.

Figure 1. Evolution of stroke severity assessed over 3 months with National Institutes of Health Stroke Scale (NIHSS) in chronic patients receiving a 3-month course of NurAiD II after an ischemic stroke





Figure 2. Evolution of post-stroke independence level assessed over 3 months with modified Rankin Scale (mRS) in chronic patients receiving a 3-month course of NurAiD II after an ischemic stroke